Atreleuton

DB12758InvestigationalSmall molecule

Atreleuton has been used in trials studying the treatment of Atherosclerosis and Coronary Artery Disease.

Mechanism: Pharmacologically active on Polyunsaturated fatty acid 5-lipoxygenase
Curator reviewed
Formula / weight: C₁₆H₁₅FN₂O₂S · 318.37 g/mol (avg)
Code names: A-85761 · A-85761.0 · ABBOTT-85761 · ABT-761 · VIA-2291

Resolves to

Compound

Structure

InChIKeyMMSNEKOTSJRTRI-LLVKDONJSA-NSMILESC[C@H](C#CC1=CC=C(CC2=CC=C(F)C=C2)S1)N(O)C(N)=O

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Atreleuton, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.